91832-40-5

• 常用中文名：头孢地尼
• 常用英文名：Cefdinir
• CAS号：91832-40-5
• 分子式：C₁₄H₁₃N₅O₅S₂
• 分子量：395.414
• 相关类别： 原料药 抗生素类药物 头孢菌素类药
• 发布时间：2018-02-07 08:00:00
• 更新时间：2026-06-30 11:18:21
• Cefdinir(Omnicef)是半合成广谱抗菌剂。

名称

• 中文名: 头孢地尼
• 英文名: cefdinir
• 中文别名: 头孢地尼,10 MM DMSO 溶液; (6R,7R)-7-[(Z)-2-(2-氨基-4-噻唑基)-2-羟基亚胺基乙酰氨基]-8-氧代-3-乙烯基-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸; (6R,7R)-7-((Z)-2-(2-氨基噻唑-4-基)-2-(羟基亚氨基)乙酰胺基)-8-氧代-3-乙烯基-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸; 头孢地尼-13C-15N2; CEFDINIR头孢地尼; (6R,7R)-7-((Z)-2-(2-氨基噻唑-4-基)-2-(肟基)乙酰胺基)-8-氧代-3-烯基-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸; 头孢地尼母核; 头孢地尼侧链(ATAABTE); Cefdinir 10mM * 1mL in DMSO试剂; 头孢地尼 标准品; [6R-[6Α,7Β(Z)]]-7-[[(2-氨基-4-噻唑基)(羟基亚氨)乙酰基]氨基]-3-乙烯基-8-氧代-5-硫杂-1-氮杂二环[4.2.0]-2-辛烯-2-羧酸; 头孢地尼/[6R-[6Α,7Β(Z)]]-7-[[(2-氨基-4-噻唑基)(羟基亚氨)乙酰基]氨基]-3-乙烯基-8-氧代-5-硫杂-1-氮杂二环[4.2.0]-2-辛烯-2-羧酸; (6R,7R)-7-[[(2-氨基-4-噻唑基)-(肟基)乙酰基]氨基]-3-乙烯基-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸
• 英文别名: (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyiMino)acetaMido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; cefdinil; Cefdinir, >=; Cefdinir (Unlabelled); FK-482; Cefodinir; To chalosporin; Cefdinir //BP; MFCD00865030; (6r-(6-alpha,7-beta(z)))-)(hydroxyiminoacetyl)amino)-3-ethenyl-8-oxo; syn-7-[2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido]-3-vinyl-3-chem-4-cboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; [6R-[6α-7beta(Z)]]-7-[[(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyimino-acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; Omnicef; Cefzon; Cefdinir >; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-, (6R,7R); Cefdinir API; Cefdinir (FK-482; cefdinyl; CFDN; TIANFUCHEM-91-5-High purity Cefdinir factory price; Cefdinir, 10 mM in DMSO; (6R,7R)-3-Vinyl-7-[(2-amino-4-thiazolyl)[(Z)-hydroxyimino]acetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]octa-2-ene-2-cboxylic acid; [6R-[6a,7b(Z)]]-7-[[(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Omicef; Cefdinib; (6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; (6R,7R)-7-{[(2E)-2-(2-Amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Novacef; (6R,7R)-7α-[[(2-Amino-4-thiazolyl)[(Z)-hydroxyimino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; [6R-[6α，7β(Z)]]_7-[[(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; EINECS 643-088-1; CEFDIRNIR; CI 983; 7-[2-(2-AMINOTHIAZOL-4-YL)-2-HYDROXYIMINOACETYLAMINO]-8-OXO-3-VINYL-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2; Cefdinir Cefdinir; CefdinirQ: What is Cefdinir Q: What is the CAS Number of Cefdinir Q: What is the storage condition of Cefdinir Q: What e the applications of Cefdinir; (6R,7R)-7-{[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Omnice; Cefdinir 15N2,13CQ: What is Cefdinir 15N2,13C Q: What is the CAS Number of Cefdinir 15N2,13C Q: What is the storage condition of Cefdinir 15N2,13C Q: What e the applications of Cefdinir 15N2,13C; (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-hydroxyimino-1-oxoethyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; bmy28488; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-, (6R,7R); 8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-cboxylicacid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-cboxylic acid, 7-(((2-amino-4-thiazolyl)(hydroxyimino acetyl)amino)-3-ethenyl-8-oxo-, (6R-(6-alpha,7-beta(Z))); 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid, 7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-, [6R-[6a,7b(Z)]]; BMY-28488, FK-482, syn-7-[2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido]-3-vinyl-3-chem-4-cboxylic acid, [6R-[6α-7beta(Z)]]-7-[[(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; (6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic Acid; CEFDINIR

物化性质

• 密度: 1.9±0.1 g/cm3
• 熔点: >180°C dec.
• 分子式: C₁₄H₁₃N₅O₅S₂
• 分子量: 395.414
• 精确质量: 395.035797
• PSA: 211.75000
• LogP: -0.63
• 外观性状: 白色粉末
• 折射率: 1.862
• 储存条件: Room temp
• 水溶解性: 水溶性：不溶；不溶：乙醇,乙醚
• 分子结构:

  1、 摩尔折射率：90.94

  2、 摩尔体积（cm³/mol）：210.2

  3、 等张比容（90.2K）：640.0

  4、 表面张力（dyne/cm）：85.8

  5、 极化率（10-24cm3）：36.05

• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:4

  3.氢键受体数量:10

  4.可旋转化学键数量:5

  5.互变异构体数量:28

  6.拓扑分子极性表面积212

  7.重原子数量:26

  8.表面电荷:0

  9.复杂度:739

  10.同位素原子数量:0

  11.确定原子立构中心数量:2

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:1

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1.性状：白色至微黄色结晶性粉末，无臭或略臭

  2熔点（分解，ºC）：170

  3.溶解性：不溶于乙醇、乙醚或水。

生物活性

• 描述: Cefdinir(Omnicef)是半合成广谱抗菌剂。
• 相关类别:
  信号通路 >> 抗感染 >> 细菌
  研究领域 >> 感染
• 参考文献:

  [1]. Soejima R. Cefdinir. Jpn J Antibiot. 1992 Oct;45(10):1239-52.

  [2]. Labro MT, et al. Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome. J Immunol. 1994 Mar 1;152(5):2447-55.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : XI0367250 CHEMICAL NAME : 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(hydroxyimino acetyl)amino)-3-ethenyl-8-oxo-, (6R-(6-alpha,7-beta(Z)))- CAS REGISTRY NUMBER : 91832-40-5 LAST UPDATED : 199806 DATA ITEMS CITED : 11 MOLECULAR FORMULA : C14-H13-N5-O5-S2 MOLECULAR WEIGHT : 395.44 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5600 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 23,93,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5600 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 23,93,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5600 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 23,93,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >2 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 23,93,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >5600 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 23,93,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >5600 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 23,93,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >5600 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 23,93,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >2 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 23,93,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >1 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,667,1995 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 18880 mg/kg SEX/DURATION : female 17 day(s) pre-mating - 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 23,5833,1989 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1100 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 23,5833,1989

安全

• 危害码 (欧洲): Xi
• 危险品运输编码: NONH for all modes of transport
• RTECS号: XI0367250
• 海关编码: 2941905990

合成路线

上下游产品

上游产品  5
104797-47-9 79349-82-9 696592-20-8 1056963-31-5
865411-26-3
下游产品  0

制备

以7-ACA为原料，对7位氨基和2位羧基保护后，再与三苯基磷反应得磷化物，它在碱性条件下与甲醛进行Wittig反应得3位的乙烯基衍生物(I)。用盐酸处理使7位的氨基游离而得化合物(Ⅱ)。在N-三甲基硅基乙酰胺存在下，化合物(Ⅱ)和4-溴乙酰乙酰溴在乙酸乙酯中，于-10℃下反应1h，得酰化产物(Ⅲ)，收率88％。化合物(Ⅲ)在二氯甲烷和乙酸中，用亚硝酸钠水溶液在-5℃亚硝化30min，再加入尿素破坏过量的亚硝酸钠，得到定量收率的羟胺化合物(Ⅳ)。化合物(Ⅳ)在N，N-二甲基乙酰胺中，和硫脲于5℃反应1h，环合得到化合物(V)。粗品化合物(V)在苯甲醚中，和三氟乙酸在5℃下反应1h，然后用水重结晶，即得头孢地尼.

海关

海关编码	2941905990